HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 64.5%

Neg 0% Neu 0% Pos 64.5%

HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $136 to $140.